Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Patent & Trademark Office (USPTO) has issued US patent 7,833,998 entitled, 'Oral Neurotherapeutic Cephalosporin Sulfoxide and Sulfone-containing Compositions' to Rexahn Pharmaceuticals.
Subscribe to our email newsletter
Rexahn Pharma said that the patent covers neurotherapeutic pharmaceutical formulation for cefazoline sulfone, cefazoline sulfoxide, ceftriaxone sulfoxide, and ceftriaxone sulfone for treating neurological disease and behavioral and cognitive disorders.
It also covers several novel compounds.
Rexahn Pharma president Rick Soni said that new patent coverage for these cefazolin and ceftriaxone groups broadens their CNS-related portfolio.